ArticleOncology reports2023
Loss of CD24 promotes radiation‑ and chemo‑resistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.
Open access · hybridAbstract read
In one paragraph
Article in Oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- MUC1 as a Survival Effector of Radiotherapy-Induced Epithelial Hybrid States in Basal-Like Breast Cancer.International journal of cancer · 2026Article
- Novel Cross-Cancer Hub Genes in Doxorubicin Resistance Identified by Transcriptional Mapping.Biomedicines · 2025Article
- Biomarkers, isolation methods, and therapeutic implications of breast cancer stem cells.Cancer pathogenesis and therapy · 2025Review
- Molecular Mechanisms of Radiation Resistance in Breast Cancer: A Systematic Review of Radiosensitization Strategies.Current issues in molecular biology · 2025Review
- Identification of cell adhesion-related subtypes and construction of risk model to predict breast cancer prognostic and immunological properties.World journal of surgical oncology · 2025Article
- Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.International journal of molecular sciences · 2025Article
- Phenotypic Plasticity and Cancer: A System Biology Perspective.Journal of clinical medicine · 2024Review
- Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence.bioRxiv : the preprint server for biology · 2024Article
- From mechanism to therapy: the journey of CD24 in cancer.Frontiers in immunology · 2024Review
- Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Isaline BontempsLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Celine LallemandLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Denis BiardUnit of Prion Disorders and Related Infectious Agents, François Jacob Institute of Biology, CEA, Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Nathalie DechampsLaboratory of Radiopathology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, CEA, French National Health and Medical Research Institute U1274, Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Thierry KortulewskiLaboratory of Radiopathology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, CEA, French National Health and Medical Research Institute U1274, Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Emmanuelle BourneufLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Capucine SiberchicotLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
François BoussinLaboratory of Radiopathology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, CEA, French National Health and Medical Research Institute U1274, Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Sylvie ChevillardLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Anna CampalansLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Jerome LebeauLaboratory of Experimental Cancerology, Institute of Cellular and Molecular Radiobiology, Genetic Stability Stem Cells and Radiation, François Jacob Institute of Biology, French Alternative Energies and Atomic Energy Commission (CEA), Paris University and Paris‑Saclay University, F‑92265 Fontenay‑aux‑Roses, France.
Institut de Radiobiologie Cellulaire et Moléculaire · FRCEA Paris-Saclay · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) serve an essential role in failure of conventional antitumor therapy. In breast cancer, CD24
Indexed as
CD24 AntigenNeoplasmsCell DifferentiationCell Line, TumorEpithelial-Mesenchymal TransitionHyaluronan ReceptorsNeoplastic Stem CellsReactive Oxygen SpeciesCD24 AntigenHyaluronan ReceptorsReactive Oxygen Speciesbreast cancercancer stem cellsCD24epithelial-mesenchymal transitionresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.